Intraocular pressure-lowering effect of 0.005% latanoprost with two different dosing regimens

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Naveed NilforushanKouros Nouri-Mahdavi

Abstract

To compare the intraocular pressure (IOP)-lowering effect of 0.005% latanoprost used once every other day versus once daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Forty eyes of 20 patients with bilateral OHT or early POAG were enrolled in this prospective, randomized, crossover study. After a washout period of 1-4 weeks, each patient started latanoprost once daily in 1 randomly assigned eye and once every other day in the other eye. After 1 month, eyes were crossed over to the opposite dosing regimen for another month. IOP was measured at 9 am, 4 pm, and 9 pm, both at baseline and on 2 consecutive days, at the end of the first and second months. The main outcome measure was IOP reduction on the second day at the end of the first and second months. Mean±standard deviation (SD) baseline IOPs (mmHg) in the right and left eye were 25.6±2.6 and 25.5±2.7 (P=0.8), respectively. Mean±SD diurnal IOPs decreased (mmHg) by 8.6±2.5 in the once-daily group versus 7.3±2.3 in the every-other-day group (P<0.001) at the end of the first month and 8.4±2.5 versus 7.7±2.5 at the end of the second month (both on day 2) (P=0.01). Once every-other-day administration of latanoprost significantly reduced the IO...Continue Reading

References

Jan 1, 1986·Archives of Ophthalmology·R H StewartR L Ward
Jun 1, 2001·American Journal of Ophthalmology·W C StewartM A Johnson
Sep 3, 2002·Survey of Ophthalmology·Lill-Inger LarssonLuca Rossetti
Sep 3, 2002·Survey of Ophthalmology·Robert A SchumerAgneta K Mandahl
Jan 14, 2003·Archives of Ophthalmology·M Cristina LeskeUNKNOWN Early Manifest Glaucoma Trial Group
Mar 22, 2003·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Robert M Feldman
Jun 11, 2003·Drugs & Aging·Caroline M PerryTim Ibbotson
Aug 24, 2004·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Shimon Kurtz, Gabi Shemesh
Jul 14, 2007·Ophthalmology·M Cristina LeskeUNKNOWN EMGT Group
Aug 10, 2007·American Journal of Ophthalmology·Alan L RobinTania S Marcic
Nov 9, 2007·American Journal of Ophthalmology·Cindy K BahlerDouglas H Johnson
Mar 20, 2009·Journal of Glaucoma·Fawzia DjafariJean Lachaine
Feb 10, 2010·Archives of Ophthalmology·Eve J HigginbothamUNKNOWN United States Fixed-Combination Study Group

❮ Previous
Next ❯

Citations

Oct 20, 2019·Survey of Ophthalmology·Kaweh MansouriRobert N Weinreb

❮ Previous
Next ❯

Software Mentioned

SAS
Stata

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.